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Abstract
Background—The COMBINE Study evaluated the effects of acamprosate, naltrexone and the
Combined Behavioral Intervention (CBI). In secondary analyses, our goals were to identify
trajectories of any drinking prior to randomization, to characterize subjects in these trajectories,
and to assess whether pre-randomization trajectories predict drinking outcomes and moderate
treatment response.
Methods—We analyzed daily indicators of any drinking in 90 days prior to randomization using
a trajectory-based approach. General linear models and generalized logistic regression assessed
main and interactive effects of pre-randomization drinking trajectories and treatment on summary
drinking measures during active treatment.
Results—We identified five trajectories of any drinking prior to randomization: “T1: frequent
drinkers”, “T2: very frequent drinkers”, “T3: nearly daily drinkers”, “T4: consistent daily
drinkers” and “T5: daily drinkers stopping early”. During treatment, “T3: nearly daily drinkers”
and “T4: consistent daily drinkers” had significantly worse drinking outcomes than “T1: frequent
drinkers” while “T5: daily drinkers stopping early” had comparable drinking outcomes to “T1:
frequent drinkers”. Acamprosate significantly increased the chance of abstinence from heavy
drinking for the “T2: very frequent drinking” trajectory but decreased the chance of abstinence
Corresponding author: Ralitza Gueorguieva, 60 College St., Room 215B, New Haven, CT 06520-8034, Tel: 203 974 7529, Fax: 203
974 7662, ralitza.gueorguieva@yale.edu.
Disclosure/Conflict of Interest:
During the period of 2008–2010, Dr. Krystal has served as a scientific consultant and/or on the Scientific Advisory Board to the
following companies: Aisling Capital, LLC, Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and
Co, Gilead Pharmaceuticals, F Hoffman-La Roche Ltd, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceuticals, Lahocla
Research Corporation, Merz Pharmaceuticals, Pfizer Pharmaceuticals, SK Holdings Co., Ltd, Takeda Industries, Teva Pharmaceutical
Industries, and Transcept Pharmaceuticals. He holds less than $10,000 in exercisable warrant options with Transcept Pharmaceuticals.
He is the principal investigator of a multicenter study in which Janssen Research Foundation has provided drug and some support to
the Department of Veterans Affairs.  He is a co-sponsor for two patents under review for glutamatergic agents targeting the treatment
of depression. Over the past 2-years, Dr. O’Malley was a member of an ACNP Workgroup sponsored by Abbott Laboratories, Eli
Lilly, Janssen, Schering Plough, Lundbeck, Glaxo-Smith Kline and Alkermes; partner in Applied Behavioral Research; consultant to
Brown University and Gilead Pharmaceuticals; NABI pharmaceutical (research contract); and received travel reimbursement from
Biological Psychiatry, the Controlled Release Society, the Drug Information Association and AMERSA. The other authors have no
potential conflicts of interest to disclose.
NIH Public Access
Author Manuscript
Alcohol Clin Exp Res. Author manuscript; available in PMC 2012 March 1.
Published in final edited form as:













from heavy drinking for “T5: daily drinkers stopping early”. Naltrexone differentially improved
rates of continuous abstinence for very frequent drinkers.
Conclusions—Acamprosate benefited very frequent drinkers and contrary to expectations was
associated with poorer response compared to placebo for consistent daily drinkers who had longer
durations of pretreatment abstinence (e.g., ≥ 14 days). Baseline drinking trajectories also
moderated naltrexone effects. These findings may help clinicians identify patients for whom
acamprosate and naltrexone may be most beneficial.
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Introduction
The COMBINE Study investigated questions related to the benefits of combining behavioral
and pharmacological interventions (Anton et al, 2006). Analyses of the primary endpoints,
time to the first day of heavy drinking and percent days abstinent, revealed that either
naltrexone or Combined Behavioral Intervention (CBI) improved outcome, but did not find
significant effects of acamprosate either alone or in combination. In a secondary trajectory-
based analyses (Gueorguieva et al, 2010), we showed that naltrexone alone, CBI alone and
the combination of naltrexone and CBI decreased the likelihood of following different post-
randomization drinking trajectories. Thus, we illustrated the advantages of such a modeling
approach in revealing additional information about the potential mechanism of treatment
effects. In this study, we apply the trajectory-based approach to identify trajectories of
drinking prior to randomization and use these as a novel measure to predict treatment
response and to evaluate trajectories as potential moderators of treatment response.
The failure to find an effect of acamprosate in the original analysis was puzzling given that
most European studies had demonstrated its efficacy (Lhuintre et al., 1990; Mason and
Ownby, 2000; Whitworth et al., 1996). Several methodological differences from the
European trials have been pointed to including the short duration of abstinence required and
the fact that very few patients in COMBINE were detoxified (Anton et al., 2006; Kiefer and
Mann, 2006). One proposed mechanism for acamprosate’s efficacy is that it dampens
glutamatergic hyperactivity related to alcohol acute and protracted withdrawal (De Witte et
al., 2003; Heilig and Egli, 2006; Mann et al., 2008). In light of this mechanism, Kiefer and
Mann (2006) have hypothesized that the COMBINE Study, by enrolling individuals who
were able to achieve 4 days of pretreatment abstinence without detoxification, may have
selected a less dependent sample that would not be responsive to acamprosate.
By evaluating baseline trajectories of drinking that capture frequency of drinking and lead-in
abstinence simultaneously, we sought to identify a subgroup of patients for whom
acamprosate would be effective. We hypothesized a priori that individuals whose baseline
drinking trajectory was characterized by consistent daily drinking and recent cessation,
compared to a trajectory of consistent daily drinking and earlier initiation of abstinence, may
benefit from acamprosate. This hypothesis was based on the assumption that glutamatergic
hyperactivity would be more pronounced during early abstinence rather than following
extended abstinence. In the COMBINE Study, participants were required to have at least
four days of abstinence and no more than 21 days, so our assessment of recency of cessation
is within these confines. Most participants achieved this without outpatient or inpatient
detoxification.
Kampman et al. (2009) compared the efficacy of acamprosate initiated during outpatient
detoxification to that of acamprosate initiated immediately following successful
Gueorguieva et al. Page 2













detoxification lasting no more than 14 days during which at least 3 days of consecutive
abstinence occurred. Their results indicated that acamprosate was more effective when
initiated following successful detoxification and at least three days of abstinence. This study
was unable to examine the influence of more extended periods of pretreatment abstinence.
We also explored whether baseline trajectories predict who benefits from naltrexone or from
the CBI. One of the debates within the naltrexone literature is whether naltrexone works best
in those who abstain prior to treatment or among those who drink on naltrexone (Sinclair,
2001; Ray et al., 2010). However, few studies have specifically examined how pretreatment
abstinence influences treatment response. A secondary analyses of a study of extended
release naltrexone (Garbutt et al., 2005; O’Malley et al., 2007) found that the effects of
naltrexone were larger in participants who had achieved a period of abstinence prior to
randomization (whether 4 or 7 days of abstinence) and that extended release naltrexone
helped maintain abstinence in these patients.
Analysis of baseline drinking trajectories may also inform the design of future
pharmacotherapy studies if we identify a trajectory that is associated with high rates of
response regardless of treatment. Exclusion of such “placebo responders” in clinical trials
could improve power to test study hypotheses.
In summary, the goals of this study were to identify trajectories of any drinking prior to
randomization in the COMBINE clinical trial, to characterize subjects in these trajectories,
and to assess whether pre-randomization trajectories predict post-randomization drinking
outcomes and whether they moderate treatment effects on these outcomes. We hypothesized
that a baseline trajectory of intensive drinking with recent cessation of alcohol prior to
enrollment would predict an increased likelihood of abstinence in response to active
acamprosate compared to placebo acamprosate. We did not have specific a priori hypotheses
regarding trajectory subgroups that would benefit from naltrexone.
Methods
The COMBINE study enrolled 1,383 abstinent alcohol dependent patients. Eight groups
received Medication Management (MM) and either placebos, naltrexone, acamprosate, or
naltrexone + acamprosate for 16 weeks. Half of these groups also received the CBI.
Participants on different treatments were comparable on seventy-six pretreatment
characteristics (Anton et al, 2006). A ninth group that received CBI alone with no pills in
order to examine placebo effects in secondary analyses is not included in this report.
The Form 90 (Miller, 1996; Miller and DelBoca, 1994) was used to retrospectively collect
daily drinking data at intake and the Timeline Follow-back interview (Sobell and Sobell,
1992, 1995) was administered at each subsequent study appointment to obtain reports of
daily drinking. Both are semi-structured interviews based on a day-by-day calendar method
to reconstruct alcohol use, allowing collection of information on days of drinking as well as
amount consumed per day. Both are comprehensive self-report measures and have good
reliability and internal consistency on summary drinking measures (Sobell and Sobell, 1992,
1995; Tonnigan et al, 1997). In this trajectory-based reanalysis we focused on baseline daily
binary indicator of drinking (1 if any drinks were consumed by the subject on that day, 0
otherwise).
Identification of baseline drinking trajectories
We used the approach of Nagin (1999) and Nagin and Tremblay (2001) to identify distinct
trajectories of drinking patterns during the 90 days prior to randomization. The models
assumed fixed polynomial trends over time within each trajectory class and the time origin
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was the day before the subjects started taking medication. The final models were obtained
via model selection (number of trajectory classes and degree of the polynomial trends over
time such as quadratic or cubic) based on the Schwartz Bayesian Criterion (BIC) and on
having at least 5% of subjects in each trajectory class. BIC is a criterion of how well the
model fits the data while keeping model complexity low. Our modeling strategy allowed the
data to guide the choice of the number of trajectories that best fit the data and to determine
the shape of each trajectory before randomization. It also allowed estimation of the
proportion of the population whose treatment response corresponds most closely to each
trajectory group. While drinking data are known to have strong 7-day periodicity, the public
use COMBINE data set does not have such information and we were not able to incorporate
periodicity into the models. For the analysis we used a customized SAS procedure (PROC
TRAJ) developed by Jones et al (2001).
Based on the final trajectory models we calculated the posterior probabilities of membership
in each trajectory class for each subject. We used categorical variables of trajectory class as
response variables in the comparisons of baseline characteristics of the identified baseline
trajectories. We also used such variables as predictors in the analyses of drinking outcomes.
Classification accuracy was assessed using the entropy measure (Muthén, 2004) with values
close to 1 indicating excellent classification of individuals to trajectory classes.
Comparison of baseline drinking trajectories on baseline characteristics
To understand the identified baseline trajectories, we compared baseline characteristics of
the subjects classified in each trajectory using ANOVA, chi-square tests and non-parametric
methods as needed. Since these analyses aimed to only characterize subjects in the different
baseline trajectories we did not apply correction for multiple tests and report significant
differences at 0.05, 0.01 and 0.001 level. Descriptive measures of drinking behavior
included the following: peak BAC (averaged over the two heaviest drinking episodes in the
90 days prior to intake), drinks per drinking day, percent days abstinent, percent heavy
drinking days and days of abstinence prior to randomization. Information about Alcoholics
Anonymous attendance, inpatient treatment or alcohol detoxification medications, legal
problems, and mental health problems for the 90 days prior to intake was obtained on the
Form90. History of alcohol withdrawal symptoms was obtained from the SCID-IV Alcohol
Module (First et al., 1997), and current symptoms were obtained using the Clinical
Withdrawal Assessment Scale- AR (Sullivan et al., 1989) administered at intake. Other
clinical assessments included the Alcohol Dependence Scale (ADS; Skinner and Allen,
1982), the total score of the Impulsive Drinking Subscale of the Drinker Inventory of
Consequences (DrInC; Miller et al., 1995) and the total score of the Obsessive Compulsive
Drinking Scale (Anton et al., 1995). Commitment to abstinence was determined from the
treatment goal question from the Thoughts about Abstinence Scale (Hall et al., 1990). A
binary variable was computed based on the response “I want to quit using alcohol once and
for all, to be totally abstinent, and never use alcohol ever again for the rest of my life” versus
all others. Participants completed these assessments at one of the intake appointments as
described in the COMBINE methods paper (COMBINE Research Group, 2003).
Predictive and moderating effects of baseline trajectories of drinking on drinking
outcomes
We modeled the effect of baseline trajectories and treatment (naltrexone, acamprosate, CBI
and their interactions) on primary post-randomization drinking outcomes using general
linear models for continuous variables and logistic regression models for binary outcomes.
Percent abstinent days and percent heavy drinking days were based on the available drinking
data from randomization through week 16. As reported in Anton et al. (2006), complete
timeline data was available for 94% of the participants. Good Clinical Outcome was defined
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as abstinence or moderate drinking without problems based on responses the Form 90 and
DrInC. Moderate drinking was defined as a maximum of 11 (women) or 14 (men) drinks per
week, with no more than 2 days on which more than 3 drinks (women) or 4 drinks (men)
were consumed. Problems were defined as endorsing 3 or more items on the DrInC
assessing physical, social, and psychological consequences of drinking.
We also analyzed the following secondary outcome measures using the same approach:
abstinence from heavy drinking in last two months of the trial and continuous abstinence
using logistic regression. Abstinence from heavy drinking following a grace period has been
proposed as an outcome measure for future clinical trials because it is associated with
reduced risk of alcohol related consequences while allowing for improvements in drinking
short of abstinence (Falk et al., 2009). We included continuous abstinence as an exploratory
outcome because this was the primary outcome used in the approval of acamprosate by the
FDA based on a reanalysis of data from three European clinical trials (Kranzler & Gage,
2008). For each drinking outcome, we performed backward elimination starting with a
model with four-way and all lower order interactions among baseline trajectories and
treatments, then dropping the four-way interaction if not significant at 0.05 level, and
dropping the three-way interactions if they were not significant at 0.05 level. Mean
differences and odds ratios were calculated for the significant interactions and main effects
in the final models. Significant effects at 0.05, 0.01 and 0.001 levels are indicated in the
tables presented in the Results section. Because this is exploratory analysis, we report all
significant effects at 0.05 level. However, a more conservative approach would be to apply
Bonferroni correction for the analysis of baseline trajectory effects on five outcome
measures. With this correction, effects at the 0.01 level would be considered significant.
Results
Identification of baseline drinking trajectories
We identified five distinct trajectories of any drinking prior to randomization (Figure 1) with
cubic polynomials describing the shapes over time. These trajectories can be referred to as
“T1: frequent drinkers”, “T2: very frequent drinkers”, “T3: nearly daily drinkers”, “T4:
consistent daily drinkers” and “T5: daily drinkers stopping early”. Entropy of the model was
excellent (0.97) thus most subjects were clearly assigned to a particular trajectory.
In all trajectories drinking declined prior to randomization as required by the criteria for
study entry but there were differences in the chance of drinking over the 90 day baseline
period and the abruptness with which drinking was discontinued prior to study entry. “T1:
frequent drinkers” (16.1% of the sample) had about a 40% chance of drinking on a particular
day. “T2: very frequent drinkers” (20.8% of the sample) had about a 75% chance of drinking
on a particular day. “T3: nearly daily drinkers” (17.9% of the sample) had between 80 and
90% chance of drinking on a particular day. “T4: consistent daily drinkers” (29% of the
sample) had virtually 100% chance of drinking on a particular day and were barely able to
stop drinking prior to study entry. In contrast “T5: daily drinkers stopping early” (16.2% of
the sample) reduced their drinking substantially at least 15 days in advance of
randomization. This might reflect repeated attempts to achieve the required four consecutive
days of abstinence prior to study entry.
Comparison of baseline drinking trajectories on baseline characteristics
Table 1 compares the five trajectories on summary measures of alcohol consumption
derived from the Form 90. The baseline characteristics of “T1: frequent drinkers” suggest a
binge pattern with less frequent but more intense drinking (e.g., high peak blood alcohol
level, more drinks per drinking day). Drinks per drinking day and peak BAC for Trajectories
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2–3 were significantly lower than for “T1: frequent drinkers”. Participants in Trajectories 2–
4 had significantly fewer days of abstinence prior to randomization than participants in “T1:
frequent drinkers” (Mean = 9.5, SD=5.7) and participants in “T5: daily drinkers stopping
early”. Subjects in “T5: daily drinkers stopping early” were drinking nearly every day,
consumed more drinks per drinking day than the other trajectories except “T1: frequent
drinkers” and had the longest duration of pre-randomization abstinence (Mean = 12.3,
SD=6.3). Baseline percent days abstinent declined across trajectories 1 through 4.
Table 2 compares the trajectory groups on demographic, treatment history, alcohol
withdrawal and alcohol-related clinical characteristics. Patients in the five trajectories varied
on numerous characteristics with the most pronounced differences observed between “T4:
consistent daily drinkers” and “T5: daily drinkers stopping early”. Participants in “T5: daily
drinkers stopping early” had higher ADS scores, higher rates of medical detoxification/
inpatient treatment, more mental health problems, greater commitment to abstinence and
attendance of Alcoholics Anonymous.
Predictive and moderating effects of baseline trajectories of drinking on drinking
outcomes
Interactions of baseline trajectories and acamprosate—We observed significant
interactions between baseline trajectory and acamprosate for good clinical outcome and
abstinence from heavy drinking in the last two months (Table 3). The acamprosate effects
stayed significant after covarying for percent days abstinent at baseline and consecutive days
abstinent prior to study entry. Thus, baseline trajectories appear to moderate acamprosate
effects albeit the results were not consistent with our a priori hypothesis.
Comparisons of acamprosate and placebo within trajectory revealed that acamprosate
significantly increased the chance of abstinence from heavy drinking for “T2: very frequent
drinkers” (OR=1.74, 95% CI: (1.04, 2.91)) but decreased the chance of abstinence from
heavy drinking for “T5: daily drinkers stopping early” (OR=0.54, 95% CI: (0.30, 0.98)).
Figure 2 illustrates this comparison. The differences between active and placebo
acamprosate were not significant for the remaining trajectories. Post-hoc tests for
acamprosate effects for good clinical outcome were not statistically significant for any of the
trajectories.
Given that acamprosate, compared to placebo, was associated with positive outcome for
individuals in “T2: very frequent drinkers” and with poorer outcome in “T5: daily drinkers
stopping early”, we conducted a logistic regression analysis via backward elimination to
determine which patient characteristics most discriminated members of these two
trajectories. Subjects in “T5: daily drinkers stopping early” were older (OR=1.03, 95% CI:
(1.01, 1.05)), had higher rates of medical detoxification/inpatient treatment (OR=1.85, 95%
CI: (1.03, 3.33)), and higher impulsive actions scores on the DrInC (OR=1.06, 95% CI:
(1.01, 1.11)). They were also less likely to be female (OR=0.45, 95% CI: (0.27, 0.76)),
weighed less (OR=0.99, 95% CI: (0.98, 1.00)) and were more likely to have elevated GGT
levels (OR=1.57, 95% CI: (1.02, 2.41)).
Interactions of baseline trajectories and naltrexone—Baseline trajectories
interacted with naltrexone in predicting continuous abstinence (Table 3 and Figure 3).
Subjects in “T5: daily drinkers stopping early” had significantly higher rate of continuous
abstinence than subjects in “T1: frequent drinkers” on naltrexone (36.5% compared to
17.1%) but not on placebo (33.3% compared to 22.8%). The effect of naltrexone was most
pronounced for subjects in “T2: very frequent drinkers” as the odds of continuous abstinence
in this trajectory were almost two times higher on naltrexone than on placebo (OR=1.88,
95% CI: (1.01, 3.48)).
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Interactions of baseline trajectories and CBI—There were no significant interactions
between baseline trajectories and CBI on any of the outcomes.
Main effects of trajectories—Our models also revealed significant main effects of
baseline trajectories of any drinking on all considered drinking outcomes (Table 3). Since
there were significant interactions involving baseline trajectories for good clinical outcome
and abstinence from heavy drinking during the last two months of treatment, we interpret
only the significant main effects for the other three outcomes. “T2: very frequent drinkers”
had significantly lower percent days abstinent than “T1: frequent drinkers”. “T3: nearly
daily drinkers” and “T4: consistent daily drinkers” had significantly poorer outcomes on
percent days abstinent, percent heavy drinking days compared to “T1: frequent drinkers”.
“T5: daily drinkers stopping early” had comparable drinking outcomes to “T1: frequent
drinkers” and had significantly better drinking outcomes than “T4: consistent daily drinkers”
for all drinking outcomes.
Exploratory Analyses of Individual Summary Drinking Variables—The potential
advantage of using trajectories rather than summary drinking measures in predicting
outcome is that trajectories capture simultaneously different aspects of drinking behavior. In
particular, the trajectories of baseline drinking identify differences in frequency of drinking
and lengths of pre-randomization abstinence. The corresponding summary drinking
variables that quantify these aspects of drinking behavior are percentage of days abstinent
(PDA) and consecutive days of abstinence prior to randomization (CDA). Neither variable
by itself was able to identify groups of subjects with positive, negative and neutral treatment
effect of acamprosate.
Guided by the results from the trajectory analyses we defined a combined categorical
variable based on CDA (CDA < 14 days vs. CDA ≥ 14 days) and PDA during the first 30
days of the 90 day pretreatment period (25% ≤ PDA < 55% vs. (PDA<25% or PDA≥55%).
We selected the first 30 days because drinking frequency appeared more stable during this
period based on visual inspection of the trajectory graphs. Furthermore, the cutoffs on both
variables were also defined based on visual inspection of the data and on the comparison of
the baseline characteristics of the subjects classified in the different trajectories. The idea
behind the creation of this variable was to separate subjects in trajectory 2 who benefited
from acamprosate, subjects in trajectory 5 for whom acamprosate was counterproductive
and the remaining subjects so that we could clearly identify subgroups with different
response to acamprosate. Then we included this categorical variable instead of trajectory
membership in the model with no heavy drinking in the last two months as the response
variable for acamprosate and continuous abstinence for naltrexone.
Using this variable we were able to observe a beneficial effect of acamprosate for subjects
with between 25% and 55% PDA (OR = 2.00, 95% CI: 1.22, 3.31), an adverse effect of
acamprosate for subjects outside of this PDA range with CDA ≥ 14 days (OR = 0.40, 95%
CI: 0.20, 0.82) and non-significant acamprosate effect for subjects with CDA <14 days and
with either small (<25%) or large (>55%) PDA (OR = 1.23, 95% CI: 0.92, 1.66). On the
other hand, naltrexone was associated with significantly better chance for continuous
abstinence than placebo for subjects with between 25% and 55% PDA (OR=1.88, 95% CI:
(1.03, 3.43)) but not for subjects outside of this range (OR = 0.97, 95% CI: 0.51, 1.84 for
subjects with PDA ≥ 14 days and OR=1.14, 95% CI: 0.76, 1.69 for subjects with PDA < 14
days).
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These exploratory trajectory-analyses identified specific patterns of drinking prior to
randomization to treatment and confirmed the hypothesis that baseline trajectories influence
post-randomization drinking outcomes. Of the five trajectories of drinking prior to
randomization, the frequency of drinking increased from “T1: frequent drinkers” to “T4:
consistent daily drinkers”. The fifth trajectory, while similar in frequency of drinking to “T4:
consistent daily drinkers” was unique and associated with stopping drinking early prior to
randomization.
As expected, baseline trajectories predicted primary and secondary outcomes during
treatment. While outcomes were most positive for the trajectory associated with the lowest
frequency of drinking (“T1: frequent heavy drinkers”) and declined across T2-T4, “T5: daily
drinkers stopping early” had very good outcomes as well. Baseline trajectories of drinking
also appear to moderate the efficacy of treatment primarily on secondary outcomes and most
notably for acamprosate. Contrary to hypotheses, individuals in “T4: consistent daily
drinkers” did not benefit from acamprosate and acamprosate decreased the odds of being
abstinent from heavy drinking in the last two months of treatment for individuals in “T5:
daily drinkers stopping early”. In contrast, acamprosate treatment was associated with
significantly higher odds of abstinence from heavy drinking for subjects in “T2: very
frequent drinkers”.
We had expected that individuals with a baseline trajectory characterized by consistent
drinking and recent cessation of drinking might experience greater withdrawal and therefore
benefit from acamprosate. However, members of “T4: consistent daily drinkers”, despite
drinking nearly daily, had the lowest proportion of patients with a history of alcohol
withdrawal, the lowest Alcohol Dependence Scale scores and were the least severe on a
number of other baseline characteristics and did not differentially benefit from acamprosate
on any of the primary or secondary outcomes. In contrast, acamprosate improved the chance
for abstinence from heavy drinking for members of “T2: very frequent drinkers”. Although
not significant, drinkers in “T3: nearly daily drinkers” experienced a similar benefit from
acamprosate. Interestingly, these groups were intermediate in terms of frequency of baseline
drinking and alcoholism severity. Although acamprosate is typically considered to promote
abstinence, Chick et al (2010) reported that acamprosate lowered the percentage of
nonabstinent drinkers who consumed 5 or more drinks per day in a secondary analysis of
data from 15 placebo controlled trials.
More puzzling, however, was the finding that acamprosate was associated with worse
drinking outcomes among patients in trajectory 5. “T5: daily drinkers stopping early” was
distinctive among the trajectories for having among the best clinical trajectories with respect
to drinking outcomes along with “T1: frequent drinkers”, despite exhibiting many other
features of chronic severe alcohol dependence, i.e., more frequent drinking, prior medical
detoxification and higher ADS scores. The capacity to initiate alcohol abstinence prior to the
required date and to sustain this abstinence until the time of randomization also
distinguished this trajectory. Stout (2000) previously demonstrated that a sustained period of
abstinence following the end of a drinking episode during treatment predicts delayed return
to drinking and heavy drinking. Our data suggest a similar relationship between pretreatment
abstinence and drinking during treatment.
The question of why acamprosate might reduce the protective effect of membership in “T5:
daily drinkers stopping early” remains open. Regardless of the mechanism, our exploratory
analyses suggest that acamprosate may not be indicated for daily drinkers who have already
achieved an extended period of pre-treatment abstinence (e.g., ≥14 days). However, the
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majority of participants attained abstinence without the aid of detoxification and so this
finding may not apply to those who begin acamprosate directly from detoxification or
through extended inpatient alcoholism treatment.
Baseline trajectories moderated naltrexone response only on the secondary outcome of
continuous abstinence. In the latter case, the odds of complete abstinence was increased for
“T2: very frequent drinkers” on naltrexone compared to placebo. Although acamprosate
studies emphasize continuous abstinence as an outcome (Kranzler & Gage, 2008; Rösner et
al, 2008) and naltrexone studies highlight effects on heavy drinking (e.g. Pettinati et al.,
2006), oral naltrexone and extended release naltrexone have been shown to enhance
abstinence in some studies (e.g., O’Malley et al., 2007; 2008). These data also suggest that
the efficacy of naltrexone does not depend exclusively on sampling alcohol (Sinclair, 2001)
at least for a subset of individuals defined on pretreatment drinking trajectories. Other
research examining frequency of drinking during treatment suggest that there may be a
subset of individuals in COMBINE who drink very regularly for whom naltrexone is
associated with reduced risk of heavy drinking (Ray et al., 2010). Because all participants in
COMBINE were required to have at least four days of abstinence, we are unable to evaluate
the effects of a baseline trajectory in which there was no pretreatment abstinence.
A secondary objective of the current study was to identify baseline trajectories of drinking
that might predict “placebo responders”. In this regard, trajectory 1, characterized by the
least frequent pretreatment drinking and trajectory 5, characterized by daily drinking but
earlier attainment of pretreatment abstinence, had the best overall outcomes. Participants in
trajectory 1 appear to engage in more binge drinking (i.e., achieving higher peak blood
alcohol levels with less frequent drinking) compared to members in trajectories 2–4.
Participants in trajectory 5 differed substantially from members of all other trajectories and
have more severe alcohol problems and higher probability of inpatient care and/or medical
detoxification. Based on this pattern of results, future studies might consider including
duration of pretreatment abstinence and/or the need for medications or hospitalization to
achieve abstinence as a stratification variable or an exclusion variable.
The potential advantage of using trajectories rather than summary drinking measures in
predicting outcome is that trajectories capture simultaneously different aspects of drinking
behavior and provide an easily interpreted graphical summary of the patterns of drinking
over time. These patterns could then be used to empirically derive combinations of summary
drinking measures, most meaningful time periods for evaluation of these variables and most
appropriate cutoffs on these variables so that subgroups with differential treatment effects
could be specified. Our analyses identified differences in frequency of drinking during the
first 30-days of the baseline period and lengths of pre-randomization abstinence among
trajectories. Guided by the results of the trajectory analyses, we were able to define
combinations of the two summary baseline variables (PDA and CDA) that serve as
moderators of treatment effects. Thus, we believe our analyses show that trajectory-based
approaches could provide useful information beyond what can be gleaned easily from
analyses of the effects of single baseline variables or other limited exploration of baseline
predictors. Other methods such as classification and regression trees can be used to assess
whether the identified combinations of variables are indeed predicting treatment outcomes
and moderating treatment effects and to explore additional combinations of summary
drinking measures that might be predictive of good outcome.
The potential clinical application of our trajectory analysis for selection of patients for
acamprosate could involve using the model we derived to estimate for a given individual the
probability of their membership within each pre-randomization drinking trajectory based on
their observed daily drinking. However, we realize that in a clinical setting it might be
Gueorguieva et al. Page 9













unrealistic to estimate trajectory membership precisely even if we provide computer code to
do this. Thus, it may be more meaningful to consider the combined categorical variable that
we derived based on the results of the trajectory analysis. Additional studies are required to
replicate these results, which could be specific to the patient population and other design
considerations.
A potential drawback of our analysis is that it is predicated on the assumption that different
classes of trajectories exist. When no categorically different trajectories exist, a substantial
percent of subjects will not be classified reliably into any one trajectory. Our good
classification accuracy gives some reassurance that in this study categorically different
classes do exist. Furthermore, the differential effects of trajectories on the outcomes and the
dissimilarities of trajectories on baseline characteristics give further reassurance that the
trajectories consist of categorically different subjects.
Sample size and population homogeneity limit the number and shape of considered
trajectories. However, since COMBINE is the largest to date study of pharmacotherapies
and behavioral therapies for alcoholism, power to detect distinct trajectories in this study is
greater than in most other studies.
In conclusion, we identified baseline trajectories of drinking that influenced post-
randomization drinking outcomes and interacted with acamprosate and with naltrexone on
secondary outcomes. Although the overall results for the COMBINE study failed to find an
effect of acamprosate, individuals with an intermediate trajectory of drinking frequency 60
to 90 days prior to beginning treatment (e.g., 25 – 55% days abstinent on an exploratory
composite index) had higher rates of no heavy drinking at the end of treatment in these
exploratory analyses. This same group had higher rates of continuous abstinence with
naltrexone compared to placebo. Contrary to prevailing hypotheses, however, acamprosate
appeared to weaken the otherwise positive prognosis of patients who had a trajectory of
consistent daily drinking and earlier abstinence initiation (e.g., 14 days or more). These
findings may help clinicians identify patients for whom acamprosate and naltrexone may be
most beneficial.
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Figure 1. Five baseline trajectories of any drinking. a
a Solid lines with symbols represent sample-based probabilities of drinking based on all
subjects weighted by the posterior probability of trajectory membership. Solid lines without
symbols represent model-based probabilities of drinking over time for each trajectory group.
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Percent abstinent from heavy drinking in the last two months by baseline trajectory and
acamprosate.
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Percent continuously abstinent by baseline trajectory and naltrexone.
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